TSLP and atopic eczema: To treat allergic dermatitis, calycosin down-regulates hypoxia-inducible factor (HIF)-1α to repair epithelial tight junctions, inhibits the TLR4-mediated NF-κB signaling pathway and reduces thymic stromal lymphopoietin (TSLP) production within the intraperitoneal injection dose range of 2–50 mg/kg in Balb/C mice and at the concentration of 10 μmol/L in HaCaT cells.